{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T18:29:27Z","timestamp":1780684167777,"version":"3.54.1"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>The impact of donor-specific anti-HLA antibodies (DSA) on antibody-mediated rejection (AMR) and kidney allograft failure is well established. However, the relevance of non-HLA antibodies remains unclear.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>We investigated 13 pretransplant non-HLA antibodies and their association with histology of AMR (AMR<jats:sub>h<\/jats:sub>) and kidney allograft failure. We included single kidney recipients (n = 203) with AMR<jats:sub>h<\/jats:sub>, according to the Banff 2017 classification and matched AMR<jats:sub>h<\/jats:sub>-free controls (n = 219). Non-HLA antibodies were assessed using multiplex Luminex assay.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>Of the selected non-HLA antibodies (against agrin, adipocyte plasma membrane-associated protein, Rho GDP-dissociation inhibitor 2 [ARHGDIB], Rho guanine nucleotide exchange factor 6, angiotensin-II type 1 receptor, endothelin type A receptor, lamin B1, BPI fold-containing family B member 1, peroxisomal trans-2-enoyl-coenzyme A reductase, phospholipase A2 receptor, protein kinase C zeta type, tubulin beta-4B class IVb, vimentin), only antibodies against ARHGDIB (adjusted median fluorescence intensity [aMFI] \u2265 1000), a minor histocompatibility antigen, associated with graft failure, in univariate and multivariate models (hazard ratio = 2.7; 95% confidence interval [CI],1.3-5.4; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.007). There was a 19.5-fold (95% CI, 6.0-63.9; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001) increased risk of graft failure in patients positive for both DSA and anti-ARHGDIB antibodies (aMFI \u2265 1000) versus patients negative for both DSA and anti-ARHGDIB antibodies, compared with a 4.4-fold (95% CI, 2.4-8.2; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001) increased risk in patients with only DSA, and a 4.1-fold (95% CI, 1.4-11.7; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.009) increased risk in patients with only anti-ARHGDIB antibodies above 2000 aMFI. AMR<jats:sub>h<\/jats:sub> associated with increased intrarenal expression of the <jats:italic toggle=\"yes\">ARHGDIB<\/jats:italic> gene. In the absence of AMR<jats:sub>h<\/jats:sub> and DSA, anti-ARHGDIB antibodies were not clearly associated with graft failure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>The presence of pretransplant anti-ARHGDIB antibodies has an additive effect in patients with DSA on the risk of graft failure via AMR<jats:sub>h<\/jats:sub>. Other investigated non-HLA antibodies, including antibodies against angiotensin-II type 1 receptor, did not contribute to risk stratification and could not explain the histology of AMR in the absence of DSA.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000003005","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T15:08:44Z","timestamp":1571843324000},"page":"1462-1471","source":"Crossref","is-referenced-by-count":37,"title":["Antibodies Against ARHGDIB and ARHGDIB Gene Expression Associate With Kidney Allograft Outcome"],"prefix":"10.1097","volume":"104","author":[{"given":"Aleksandar","family":"Senev","sequence":"first","affiliation":[{"name":"Histocompatibility and Immunogenetics Laboratory, Red Cross-Flanders, Mechelen, Belgium."},{"name":"Department of Microbiology, Immunology and Transplantation, KU Leuven, University of Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henny G.","family":"Otten","sequence":"additional","affiliation":[{"name":"Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena G.","family":"Kamburova","sequence":"additional","affiliation":[{"name":"Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Callemeyn","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, KU Leuven, University of Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Lerut","sequence":"additional","affiliation":[{"name":"Department of Imaging & Pathology, University Hospitals Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Van Sandt","sequence":"additional","affiliation":[{"name":"Histocompatibility and Immunogenetics Laboratory, Red Cross-Flanders, Mechelen, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Kuypers","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, KU Leuven, University of Leuven, Belgium."},{"name":"Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Paule","family":"Emonds","sequence":"additional","affiliation":[{"name":"Histocompatibility and Immunogenetics Laboratory, Red Cross-Flanders, Mechelen, Belgium."},{"name":"Department of Microbiology, Immunology and Transplantation, KU Leuven, University of Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Naesens","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, KU Leuven, University of Leuven, Belgium."},{"name":"Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"2","key":"R1-20231002","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence.","volume":"12","author":"Sellar\u00e9s","year":"2012","journal-title":"Am J Transplant"},{"issue":"1","key":"R2-20231002","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/TP.0b013e3181e065de","article-title":"Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure.","volume":"90","author":"Gaston","year":"2010","journal-title":"Transplantation"},{"issue":"4","key":"R3-20231002","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/TP.0000000000000183","article-title":"The histology of kidney transplant failure: a long-term follow-up study.","volume":"98","author":"Naesens","year":"2014","journal-title":"Transplantation"},{"issue":"12","key":"R4-20231002","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1056\/NEJMra1802677","article-title":"Antibody-mediated rejection of solid-organ allografts.","volume":"379","author":"Loupy","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"R5-20231002","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/ajt.15074","article-title":"Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: clinical presentation and implications for outcome.","volume":"19","author":"Senev","year":"2019","journal-title":"Am J Transplant"},{"issue":"4","key":"R6-20231002","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1681\/ASN.2018080868","article-title":"Early acute microvascular kidney transplant rejection in the absence of anti-HLA antibodies is associated with preformed IgG antibodies against diverse glomerular endothelial cell antigens.","volume":"30","author":"Delville","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"R7-20231002","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1111\/ajt.13347","article-title":"Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody.","volume":"15","author":"Wiebe","year":"2015","journal-title":"Am J Transplant"},{"issue":"7","key":"R8-20231002","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1097\/TP.0000000000002487","article-title":"Clinical significance of microvascular inflammation in the absence of anti-HLA DSA in kidney transplantation.","volume":"103","author":"Parajuli","year":"2019","journal-title":"Transplantation"},{"issue":"8","key":"R9-20231002","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1097\/TP.0000000000002743","article-title":"Is there a role for natural antibodies in rejection following transplantation?","volume":"103","author":"Zorn","year":"2019","journal-title":"Transplantation"},{"issue":"9470","key":"R10-20231002","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/S0140-6736(05)66458-6","article-title":"Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies.","volume":"365","author":"Opelz","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"R11-20231002","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/00007890-198810000-00024","article-title":"Hyperacute allograft rejection mediated by anti-vascular endothelial cell antibodies with a negative monocyte crossmatch.","volume":"46","author":"Jordan","year":"1988","journal-title":"Transplantation"},{"issue":"6","key":"R12-20231002","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1111\/j.1600-6143.2011.03955.x","article-title":"Multiple hyperacute rejections in the absence of detectable complement activation in a patient with endothelial cell reactive antibody.","volume":"12","author":"Jackson","year":"2012","journal-title":"Am J Transplant"},{"issue":"10","key":"R13-20231002","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1097\/TP.0b013e3181891d8b","article-title":"Endothelial cells in allograft rejection.","volume":"86","author":"Al-Lamki","year":"2008","journal-title":"Transplantation"},{"issue":"2","key":"R14-20231002","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/ctr.12665","article-title":"Clinical relevance of preformed IgG and IgM antibodies against donor endothelial progenitor cells in recipients of living donor kidney grafts.","volume":"30","author":"Daniel","year":"2016","journal-title":"Clin Transplant"},{"issue":"11","key":"R15-20231002","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.humimm.2013.06.007","article-title":"A prospective study evaluating the role of donor-specific anti-endothelial crossmatch (XM-ONE assay) in predicting living donor kidney transplant outcome.","volume":"74","author":"Zitzner","year":"2013","journal-title":"Hum Immunol"},{"issue":"8","key":"R16-20231002","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/TP.0b013e3181889748","article-title":"Humoral responses directed against non-human leukocyte antigens in solid-organ transplantation.","volume":"86","author":"Dragun","year":"2008","journal-title":"Transplantation"},{"issue":"4","key":"R17-20231002","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.trre.2016.06.001","article-title":"Clinical value of non-HLA antibodies in kidney transplantation: still an enigma?","volume":"30","author":"Michielsen","year":"2016","journal-title":"Transplant Rev (Orlando)"},{"issue":"19","key":"R18-20231002","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJM200505123521921","article-title":"Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.","volume":"352","author":"Ansari","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"R19-20231002","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.kint.2017.06.034","article-title":"Angiotensin II type 1 receptor antibodies are associated with inflammatory cytokines and poor clinical outcomes in pediatric kidney transplantation.","volume":"93","author":"Pearl","year":"2018","journal-title":"Kidney Int"},{"issue":"12","key":"R20-20231002","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1097\/TP.0b013e3181fd97f1","article-title":"Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients.","volume":"90","author":"Reinsmoen","year":"2010","journal-title":"Transplantation"},{"issue":"3","key":"R21-20231002","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/TP.0000000000001231","article-title":"Anti-angiotensin II type 1 receptor and anti-endothelial cell antibodies: a cross-sectional analysis of pathological findings in allograft biopsies.","volume":"101","author":"Philogene","year":"2017","journal-title":"Transplantation"},{"issue":"2","key":"R22-20231002","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/ajt.14625","article-title":"The Banff 2017 kidney meeting report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.","volume":"18","author":"Haas","year":"2018","journal-title":"Am J Transplant"},{"issue":"11","key":"R23-20231002","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1097\/TP.0000000000002366","article-title":"A 2018 reference guide to the Banff classification of renal allograft pathology.","volume":"102","author":"Roufosse","year":"2018","journal-title":"Transplantation"},{"key":"R24-20231002","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.3389\/fimmu.2018.03002","article-title":"Development and validation of a multiplex non-HLA antibody assay for the screening of kidney transplant recipients.","volume":"9","author":"Kamburova","year":"2018","journal-title":"Front Immunol"},{"key":"R25-20231002","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1111\/ajt.15493","article-title":"Antibodies against ARHGDIB are associated with long-term kidney graft loss.","volume":"19","author":"Kamburova","year":"2019","journal-title":"Am J Transplant"},{"key":"R26-20231002","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1111\/ajt.15414","article-title":"Specificity, strength and evolution of pretransplant donor-specific HLA antibodies determine outcome after kidney transplantation.","volume":"19","author":"Senev","year":"2019","journal-title":"Am J Transplant"},{"issue":"1","key":"R27-20231002","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.kint.2018.08.027","article-title":"Natural killer cell infiltration is discriminative for antibody-mediated rejection and predicts outcome after kidney transplantation.","volume":"95","author":"Yazdani","year":"2019","journal-title":"Kidney Int"},{"issue":"12","key":"R28-20231002","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0968-0004(96)10062-1","article-title":"Structural insights into the function of the Rab GDI superfamily.","volume":"21","author":"Wu","year":"1996","journal-title":"Trends Biochem Sci"},{"issue":"22","key":"R29-20231002","doi-asserted-by":"crossref","first-page":"9073","DOI":"10.1158\/0008-5472.CAN-10-1832","article-title":"High-throughput characterization of 10 new minor histocompatibility antigens by whole genome association scanning.","volume":"70","author":"Van Bergen","year":"2010","journal-title":"Cancer Res"},{"issue":"16","key":"R30-20231002","doi-asserted-by":"crossref","first-page":"7568","DOI":"10.1073\/pnas.90.16.7568","article-title":"Ly-GDI, a GDP-dissociation inhibitor of the rhoa GTP-binding protein, is expressed preferentially in lymphocytes.","volume":"90","author":"Scherle","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3-4","key":"R31-20231002","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10555-009-9197-4","article-title":"Pathways of metastasis suppression in bladder cancer.","volume":"28","author":"Said","year":"2009","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"R32-20231002","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1021\/pr900930d","article-title":"Identification of non-HLA antigens targeted by alloreactive antibodies in patients undergoing chronic hemodialysis.","volume":"9","author":"Bilalic","year":"2010","journal-title":"J Proteome Res"},{"issue":"5","key":"R33-20231002","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/01.TP.0000436927.08026.a8","article-title":"Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome.","volume":"97","author":"Reinsmoen","year":"2014","journal-title":"Transplantation"},{"issue":"1","key":"R34-20231002","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.kint.2019.01.030","article-title":"Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients.","volume":"96","author":"Lefaucheur","year":"2019","journal-title":"Kidney Int"},{"issue":"11","key":"R35-20231002","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/tri.13009","article-title":"Is pre-transplant sensitization against angiotensin II type 1 receptor still a risk factor of graft and patient outcome in kidney transplantation in the anti-HLA luminex era? A retrospective study.","volume":"30","author":"Deltombe","year":"2017","journal-title":"Transpl Int"},{"issue":"5-6","key":"R36-20231002","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.humimm.2017.03.012","article-title":"Assessing the potential of angiotensin II type 1 receptor and donor specific anti-endothelial cell antibodies to predict long-term kidney graft outcome.","volume":"78","author":"Pinelli","year":"2017","journal-title":"Hum Immunol"},{"issue":"11","key":"R37-20231002","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1111\/ajt.14753","article-title":"Xenoreactive antibodies and latent fibrin formation in VAD and cardiac transplant recipients can confound the detection and measurement of anti-AT1R antibodies.","volume":"18","author":"Oaks","year":"2018","journal-title":"Am J Transplant"},{"issue":"10174","key":"R38-20231002","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S0140-6736(18)32473-5","article-title":"Contribution of non-HLA incompatibility between donor and recipient to kidney allograft survival: genome-wide analysis in a prospective cohort.","volume":"393","author":"Reindl-Schwaighofer","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"R39-20231002","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.3324\/haematol.2015.125021","article-title":"LB-ARHGDIB-1R as a novel minor histocompatibility antigen for therapeutic application.","volume":"100","author":"Pont","year":"2015","journal-title":"Haematologica"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:11:58Z","timestamp":1696223518000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000003005","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}